Feasibility of a Bihormonal Closed-Loop System to Control Postexercise and Postprandial Glucose Excursions

Background: The aim of this pilot study was to test the feasibility of a bihormonal (glucagon and insulin) closed-loop (CL) system by challenging the system with two meals and 30 min exercise. Methods: Ten patients with type 1 diabetes treated with continuous subcutaneous insulin infusion underwent a standardized protocol on three different occasions: 40 g carbohydrate breakfast followed 2 h later by 30 min of moderate-intensity exercise, followed 1.5 h later by a standardized 60 g carbohydrate lunch. An open-loop (OL) day served as control, the first CL day as tuning experiment, and the second CL day to compare with OL. Results: The overall mean venous glucose was similar: 9 (5.4–13.5) mmol/liter in OL versus 8.7 (6.4–11.0) mmol/liter in CL, p = .74. The postbreakfast glucose concentrations tended to be lower in OL than in CL [9.5 (4.3–13.3) versus 11.4 (7–16.2) mmol/liter; p = .07] and higher in OL than in CL postlunch [9.4 (6.0–14.9) versus 7.7 (5.5–9.0) mmol/liter, p = .15]. The postexercise glucose concentrations were similar in OL and CL: 7.5 (4.6–13) versus 8.2 (5.5–13.1) mmol/liter; p = .45. In those patients coming in with baseline glucose above 7 mmol/liter, there was initial overinsulinization in CL. During OL, two hypoglycemic episodes occurred compared with four hypoglycemic episodes in three participants during CL. Glucagon seemed mostly effective in preventing hypoglycemia. Conclusions: Overall, CL glucose control was comparable to OL control, but there was overinsulinization in those patients with baseline glucose above 7 mmol/liter.

[1]  W. Kenneth Ward,et al.  Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes , 2010, Diabetes Care.

[2]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[3]  Aaron J. Kowalski,et al.  Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. , 2009, Diabetes technology & therapeutics.

[4]  Robert G. Sutherlin,et al.  A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes , 2010, Science Translational Medicine.

[5]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[6]  L. Magni,et al.  Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results , 2010, Journal of diabetes science and technology.

[7]  M. Seger,et al.  Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. , 1999, Journal of pharmaceutical sciences.

[8]  J. Stockman,et al.  Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial , 2011 .

[9]  J Hans DeVries,et al.  Postprandial Glycemic Excursions with the Use of a Closed-Loop Platform in Subjects with Type 1 Diabetes: A Pilot Study , 2010, Journal of diabetes science and technology.